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PUBLIC HEALTH STUDY AIMS to
INCREASE HPV VACCINATIONS
Too often, cultural, educational and
demographic barriers hamper the public’s
use of vaccines. Among the most prominent
examples is the human papillomavirus vaccine
(HPV): roughly half of U.S. adolescents are not
vaccinated and remain vulnerable to the virus
and the cancers it causes.
“You’d have a hard time finding a parent
who doesn't want to protect their child from
cancer,” observes Amy Leader, DrPH, MPH,
associate professor of population science.
“Still, many parents are missing an opportunity
to protect their children from HPV, the most
common sexually transmitted infection and a
leading cause of cancers.”
Dr. Leader is deeply engaged in developing
and studying new approaches to increase HPV
vaccination rates among high-risk populations.
She and her colleagues recently completed an
NIH-funded study on strategies to increase HPV
vaccination rates among vulnerable populations
in the Philadelphia region.

The study had three aims. The first sought
to identify barriers to HPV vaccination in
Hispanic and African immigrant communities.
The researchers found that, despite a high
level of awareness of the HPV vaccine among
the broader Philadelphia-area population,
members of marginalized communities had
much lower awareness of the vaccine’s
availability and effectiveness, and received far
less information through media, community
and public health channels.
The second aim used citywide vaccination
records and data on social determinants of
health to identify novel predictors of HPV
vaccination; initial analyses suggest several
predictors, including neighborhood-level
economic stability.
The project’s final aim sought to better
understand the content and nature of public
discourse about HPV vaccination on social
media channels. The team found that antivaccine messaging was delivered most

often—and very effectively—through narrative
communication (in other words, storytelling).
In contrast, pro-vaccine messaging tended to
be built around objective data, which was less
compelling to many audiences.
“The data suggests that public health
messaging needs to be more engaging, more
focused on telling people’s stories than on
conveying nuts-and-bolts facts,” Leader
notes. To test that hypothesis, she and her
colleagues are undertaking an NIH-funded
randomized controlled trial that uses Twitter
to communicate either science-based content
or narrative messages that prompt feelings of
empathy, transportation, and identification.
Subsequently, they will then track the rates of
adolescent HPV vaccination.
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